drug
(empagliflozin + linagliptin)
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
Type 2 Diabetes
all catalysts(21)
approval · 21
Jan 30, 2015
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Aug 28, 2015
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 4, 2015
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jul 8, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 23, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 23, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 14, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Aug 10, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Aug 10, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 13, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 26, 2018
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jul 1, 2019
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jul 3, 2019
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jan 24, 2020
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 30, 2020
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jun 11, 2021
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jun 11, 2021
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 21, 2022
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 13, 2022
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 30, 2023
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 24, 2025
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Trials studying (empagliflozin + linagliptin)
- phase1To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
- phase1Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 15, 2027
236 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (50)
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Jun 11, 2034method-of-use (U-2290)US 9949998
- Jun 11, 2034method-of-use (U-2290)US 9949998
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-3191)US 11090323
- Apr 3, 2034method-of-use (U-3191)US 11090323
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Aug 11, 2030patentUS 12115179*PED4.0y
- Aug 11, 2030patentUS 12115179*PED4.0y
- Apr 14, 2030patentUS 8551957*PED3.6y
- Apr 14, 2030patentUS 8551957*PED3.6y
- Feb 11, 2030method-of-use (U-4023)US 121151793.5y
- Feb 11, 2030method-of-use (U-4023)US 121151793.5y
- Oct 14, 2029formulationUS 85519573.1y
- Oct 14, 2029formulationUS 85519573.1y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Aug 1, 2028compositionUS 75794491.9y
- Aug 1, 2028compositionUS 75794491.9y
- Nov 4, 2027patentUS 11033552*PED1.2y
- Nov 4, 2027patentUS 11033552*PED1.2y
- Nov 4, 2027patentUS 8673927*PED1.2y
- Nov 4, 2027patentUS 8673927*PED1.2y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Oct 15, 2027patentUS 7713938*PED1.1y
- May 4, 2027formulationUS 11033552255d
- May 4, 2027formulationUS 11033552255d
- May 4, 2027formulationUS 12178819255d
- May 4, 2027formulationUS 12178819255d
- Apr 15, 2027compositionUS 7713938236d
- Apr 15, 2027compositionUS 7713938236d
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that